Inhibition of bacteria on agar surfaces by vapour phase triclosan.

314 4. Smith, H. J., Nichol, K. A., Hoban, D. J. et al. (2002). Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. Journal of Antimicrobial Chemotherapy 49, 893–5. 5. Heaton, V. J., Ambler, J. E. & Fisher, L. M. (2000). Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, and in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrobial Agents and Chemotherapy 44, 3112–7. 6. Pan, X.-S. & Fisher, L. M. (1998). DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 42, 2810–6. 7. Brueggemann, A. B., Coffman, S. L., Rhomberg, P. et al. (2002). Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994–1995. Antimicrobial Agents and Chemotherapy 46, 680–8. 8. Zhanel, G. G., Walkty, A., Nichol, K. et al. (2003). Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagnostic Microbiology and Infectious Disease 45, 63–7. 9. Smith, H. J., Nichol, K. A., Walkty, A. et al. (2002). Different contribution of efflux to fluoroquinolone resistance in clinical isolates and laboratory-created mutants of Streptococcus pneumoniae. In Programs and Abstracts of the Hundred and Second American Society for Microbiology General Meeting, Salt Lake City, UT, 2002. Abstract A-18, p.43. American Society for Microbiology, Washington, DC, USA. 10. Zhanel, G. G., Hoban D. J. & Chan C. K. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 347, 66. 11. Davidson, R., Cavalcanti, R., Brunton J. L. et al. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 346, 747–50.